Publication related to RSI or an RSI staff member

Recent Advances in Probabilistic Dose-Response Assessment to Inform Risk-Based Decision Making.

Authors

  • Chiu, Weihsueh A, Chiu WA, Texas A&M University, College Station, TX, USA.

  • Paoli, Greg M, Paoli GM, Risk Sciences International, Ottawa, ON, Canada.

YEAR OF PUBLICATION: 2021
SOURCE: Risk Anal. 2021 Apr;41(4):596-609. doi: 10.1111/risa.13595. Epub 2020 Sep 23.
JOURNAL TITLE ABBREVIATION: Risk Anal
JOURNAL TITLE: Risk analysis : an official publication of the Society for Risk Analysis
ISSN: 1539-6924 (Electronic) 0272-4332 (Print) 0272-4332 (Linking)
VOLUME: 41
ISSUE: 4
PAGES: 596-609
PLACE OF PUBLICATION: United States
ABSTRACT:

Paradoxically, risk assessments for the majority of chemicals lack any quantitative characterization as to the likelihood, incidence, or severity of the risks involved. The relatively few cases where "risk" is truly quantified are based on either epidemiologic data or extrapolation of experimental animal cancer bioassay data. The paucity of chemicals and health endpoints for which such data are available severely limits the ability of decisionmakers to account for the impacts of chemical exposures on human health. The development by the World Health Organization International Programme on Chemical Safety (WHO/IPCS) in 2014 of a comprehensive framework for probabilistic dose-response assessment has opened the door to a myriad of potential advances to better support decision making. Building on the pioneering work of Evans, Hattis, and Slob from the 1990s, the WHO/IPCS framework provides both a firm conceptual foundation as well as practical implementation tools to simultaneously assess uncertainty, variability, and severity of effect as a function of exposure. Moreover, such approaches do not depend on the availability of epidemiologic data, nor are they limited to cancer endpoints. Recent work has demonstrated the broad feasibility of such approaches in order to estimate the functional relationship between exposure level and the incidence or severity of health effects. While challenges remain, such as better characterization of the relationship between endpoints observed in experimental animal or in vitro studies and human health effects, the WHO/IPCS framework provides a strong basis for expanding the breadth of risk management decision contexts supported by chemical risk assessment.

COPYRIGHT INFORMATION: (c) 2020 Society for Risk Analysis.
LANGUAGE: eng
DATE OF PUBLICATION: 2021 Apr
DATE OF ELECTRONIC PUBLICATION: 20200923
DATE COMPLETED: 20220114
DATE REVISED: 20220402
MESH DATE: 2022/01/15 06:00
EDAT: 2020/09/24 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1111/risa.13595 [doi]
MANUSCRIPT IDENTIFIER: NIHMS1720646
OWNER: NLM

Related RSI Experts

Greg Paoli

CEO, Principal Risk Scientist

Greg Paoli is the CEO and Principal Risk Scientist at Risk Sciences International (RSI), a firm he co-founded in 2006 following the integration of his earlier consultancy, Decisionalysis Risk Consultants, with the consulting activities of the McLaughlin Centre for Population...
Read More about Greg Paoli